Status:
RECRUITING
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Lead Sponsor:
Ascendis Pharma Endocrinology Division A/S
Conditions:
Growth Hormone Deficiency
Eligibility:
All Genders
1-18 years
Brief Summary
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Detailed Description
Patients will be treated according to routine clinical practice, and no additional visits, examinations or tests will be required beyond those performed as part of routine clinical practice except for...
Eligibility Criteria
Inclusion Criteria:
- Patients who are on treatment with SKYTROFA (lonapegsomatropin)
- Patients being clinically managed in USA
- Patients with an appropriate written informed consent/assent as applicable for the age of the patient
Exclusion Criteria:
- Patients participating in any interventional clinical study
Key Trial Info
Start Date :
March 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2033
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT05820672
Start Date
March 20 2023
End Date
March 1 2033
Last Update
February 4 2026
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Ascendis Investigational Site
Phoenix, Arizona, United States, 85054
2
Ascendis Investigational Site
Orange, California, United States, 92868
3
Ascendis Investigational Site
Sacramento, California, United States, 95821
4
Ascendis Investigational Site
San Francisco, California, United States, 94143